These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 37464337)

  • 1. Blended smartphone intervention for patients in opioid maintenance treatment in Iran: protocol for a randomized controlled trial.
    Boumparis N; Noroozi A; Naghizadeh E; Meyer A; Wenger A; Rahimi-Movaghar A; Schaub MP
    BMC Psychiatry; 2023 Jul; 23(1):518. PubMed ID: 37464337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substance of choice, impact of heroin or opium on treatment retention in a multicentre randomised controlled trial in Iran.
    Song MJ; Westenberg JN; Kianpoor K; Nikoo M; Kazemi A; Schuetz C; Jang K; Gholami A; Akhondzadeh S; Krausz M
    Drug Alcohol Rev; 2022 May; 41(4):895-901. PubMed ID: 35170124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
    Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
    Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial.
    Marsden J; Stillwell G; James K; Shearer J; Byford S; Hellier J; Kelleher M; Kelly J; Murphy C; Mitcheson L
    Lancet Psychiatry; 2019 May; 6(5):391-402. PubMed ID: 30952568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial.
    Thompson RG; Bollinger M; Mancino MJ; Hasin D; Han X; Bush KA; Kilts CD; James GA
    Trials; 2023 Apr; 24(1):255. PubMed ID: 37016394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in substance use among patients in opioid maintenance treatment: baseline to 1-year follow-up.
    Bjørnestad ED; Vederhus JK; Clausen T
    Harm Reduct J; 2024 May; 21(1):101. PubMed ID: 38790008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: Study protocol for a pragmatic randomised controlled trial.
    Marsden J; Stillwell G; Hellier J; Brown AM; Byford S; Kelleher M; Kelly J; Murphy C; Shearer J; Mitcheson L
    Contemp Clin Trials; 2017 Feb; 53():36-43. PubMed ID: 27940188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing engagement and utilisation of opium tincture-assisted treatment for opioid use disorder: A qualitative study in Tehran, Iran.
    Noroozi A; Conigrave KM; Mirrahimi B; Bastani P; Charkhgard N; Salehi M; Narenjiha H; Vaziri A; Kebriaeezadeh A
    Drug Alcohol Rev; 2022 Feb; 41(2):419-429. PubMed ID: 34309108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial.
    Nikoo M; Moazen-Zadeh E; Nikoo N; Javidanbardan S; Kazemi A; Choi F; Vogel M; Gholami A; Tavakoli S; Givaki R; Jazani M; Mohammadian F; Markazi Moghaddam N; Goudarzi N; Schutz C; Jang K; Akhondzadeh S; Krausz M
    Int J Methods Psychiatr Res; 2019 Mar; 28(1):e1768. PubMed ID: 30714249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stigma and level of familiarity with opioid maintenance treatment (OMT) among specialist physicians in Israel.
    Lihi R; Yael D; Silviu B; Anat S; Marsha W; Stacy S; Shaul S; Miriam A; Einat P
    Harm Reduct J; 2023 Sep; 20(1):134. PubMed ID: 37715237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine.
    Heikman PK; Muhonen LH; Ojanperä IA
    BMC Psychiatry; 2017 Jul; 17(1):245. PubMed ID: 28683783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Who receives heroin-assisted treatment? A comparison of patients receiving opioid maintenance treatment in Denmark.
    Melis F; Hesse M; Eide D; Thylstrup B; Tjagvad C; Brummer JE; Clausen T
    Drug Alcohol Depend; 2024 Jan; 254():111051. PubMed ID: 38091901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment.
    Belcher AM; Cole TO; Greenblatt AD; Hoag SW; Epstein DH; Wagner M; Billing AS; Massey E; Hamilton KR; Kozak ZK; Welsh CJ; Weintraub E; Wickwire EM; Wish ED; Kaptchuk TJ; Colloca L
    BMJ Open; 2019 Jun; 9(6):e026604. PubMed ID: 31230007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders.
    Carney T; Van Hout MC; Norman I; Dada S; Siegfried N; Parry CD
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012254. PubMed ID: 32068247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychosocial intervention utilization and substance abuse treatment outcomes in a multisite sample of individuals who use opioids.
    Harvey LM; Fan W; Cano MÁ; Vaughan EL; Arbona C; Essa S; Sanchez H; de Dios MA
    J Subst Abuse Treat; 2020 May; 112():68-75. PubMed ID: 32199548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial.
    Holland R; Maskrey V; Swift L; Notley C; Robinson A; Nagar J; Gale T; Kouimtsidis C
    Addiction; 2014 Apr; 109(4):596-607. PubMed ID: 24304349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collaborative care in the treatment of opioid use disorder and mental health conditions in primary care: A clinical study protocol.
    Harris RA; Mandell DS; Kampman KM; Bao Y; Campbell K; Cidav Z; Coviello DM; French R; Livesey C; Lowenstein M; Lynch KG; McKay JR; Oslin DW; Wolk CB; Bogner HR
    Contemp Clin Trials; 2021 Apr; 103():106325. PubMed ID: 33631356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attention Deficit Hyperactivity Disorder Symptoms are Common in Patients in Opioid Maintenance Treatment.
    Fiksdal Abel K; Ravndal E; Clausen T; Bramness JG
    Eur Addict Res; 2017; 23(6):298-305. PubMed ID: 29320768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in self-reported somatic symptoms among patients in opioid maintenance treatment from baseline to 1-year follow-up.
    Bjørnestad ED; Vederhus JK; Clausen T
    BMC Psychiatry; 2024 Feb; 24(1):149. PubMed ID: 38383345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.